002603 Shijiazhuang Yiling Pharmaceutical
- 16.31
- +0.14+0.87%
About Shijiazhuang Yiling Pharmaceutical Company
The company was founded on June 16, 1992. The company took “inheriting innovation and benefiting humanity” as the corporate purpose, “science and technology for a healthy tomorrow”, “seeking development for employees, contributing to society, and creating value for shareholders” as the business philosophy, always adhering to the innovative development strategy of leading technology and market leaders. For the first time, the company systematically constructed a complex disease theory system, and founded a five-in-one “theory - clinical research - industry - teaching” industrial development cluster “from medicine to medicine to health”. “Traditional Chinese medicine complex disease diagnosis and treatment methods” are included in the national intangible cultural Heritage, Complexology 》It became a university textbook, and courses have been launched at more than 40 colleges and universities across the country. The company's main business is R&D, production and sales of patented innovative traditional Chinese medicines. The company's main products include Tongxinluo capsules, Shensong Yangxin capsules, Qiangxin capsules, Lianhua Qingfeng capsules, Lianhua Qingfeng capsules, Lianhua Cough tablets, Jinlida granules, Tongluo Mingmu capsules, Kidney Health Relief Tablets, Antidepressant capsules, Zizheng Anshen Oral Liquid OTC products, Yangzheng Anshen capsules, Shenling Blue capsules, Bazi Kidney Supplements capsules, Xia Li Qi capsules, etc. Corporate honors: Ranked first in the “2023 Chinese Medicine Innovative Brand Enterprise” list, won the “Top 100 Most Valuable Companies on the Main Board”, was selected for the “Top 100 Companies in China Pharmaceutical Industry Quality Award”, selected as “2023 Top 30 Pharmaceutical Industry Competitiveness”, ranked 5th in the 2022 Chinese Traditional Chinese Medicine Enterprise TOP100 list, selected for the CCTV “China ESG Listed Companies Pioneer 100” list, and was selected for the China Top 100 Innovative Brands, selected for the Xinhua News Agency Brand Project, Hebei Enterprise Technology Innovation Award, National Advanced Private Enterprise for Employment and Social Security, 2020 In July, Eling Pharmaceutical ranked 10th in the “2019 Top 100 Chinese Medicine Companies List” (China Pharmaceutical Industry Top 100 Series List) and won the honorary title of “High-Level Innovation Team”.
Company Profile
Company Executives
- Name
- Position
- Salary
- xiangjun wu
- Chairman, directors, general manager, Strategy and Planning Committee (convener), Nomination Committee Members
- 3.15M
- rui wu
- Directors, Board Secretary, Member of the Strategy and Planning Committee
- 1.83M
- qiulian zhang
- Directors, Deputy General Manager
- 2.16M
- weidong xu
- Directors, Member of the Remuneration and Assessment Committee
- 939.10K
- chenguang li
- Directors, Head of Finance, Member of the Strategy and Planning Committee
- 1.83M
- shaohua zhao
- Directors
- 971.80K
- xiaohan liu
- Independent directors, Member of the Strategy and Planning Committee, Member of the Remuneration and Assessment Committee, Nomination Committee (Convener), Audit Committee Member
- 116.60K
- zhenguo chai
- Independent directors, Audit Committee Member, Member of the Remuneration and Assessment Committee (Convener), Nomination Committee Members
- --
- gang chen
- Independent directors, Audit Committee Member (Convener)
- 100.00K
- hua wang
- Securities Affairs Representative
- --
- xuedong gao
- Chairman of the Supervisory Board, Auditors
- 1.31M
- genwu liu
- Auditors
- 452.10K
- xiaolin zhou
- Deputy General Manager
- 1.41M
- keyuan zhang
- Deputy General Manager
- 1.86M
- wei wang
- Deputy General Manager
- 944.90K
- ruihua niu
- Employee Supervisors
- 578.80K
No Data
